Today, glucocorticoids (GCs) are still included in the various treatment cocktails that are used to treat both newly and relapsed diagnosed multiple myeloma patients. Unfortunately, the administration of GCs is associated with adverse effects if high doses are administered for a long period of time. GC resistance is one of these adverse effects that could lead to relapse. Therefore, finding potential candidate biomarkers associated with GC resistance could improve the prediction of the medical outcome of the patient. The timely detection of GC resistance via biomarkers would allow physicians to intervene and change the treatment in time to ensure that patients no longer unnecessarily suffer from the GC-related side effects and that relapse may be postponed. Regular screening for a biomarker during GC treatment and tight follow-up could make patients less likely to return to the hospital with a more severe form of the disease. In extension, this could avoid prolonged hospitalizations and consequently the health sector expenses could drop as well. On top of that, the patient’s mental well-being may improve as well because GCs cause psychological disturbances which in turn affects their loved ones but could also ensure that the patient remains productive within the community which benefits the economy. In addition, our research could provide a starting point for other pharmaceutical companies to develop new drugs that might target the newly discovered biomarker and, in that way, also contributes to our economy.